Abstract 71P
Background
CD70 is an attractive tumor target due to its over-expression in numerous solid and hematological cancers and limited expression in healthy cells. In the last decade, multiple anti-CD70 antibody drug conjugates (ADCs) have been developed, but most have been discontinued due to unacceptable toxicity or a narrow therapeutic index. Using an expanded genetic code to create Engineered Precision Biologics, Ambrx has developed ARX305, a CD70-targeted next-generation ADC to potentially overcome the challenges associated with earlier ADCs. ARX305 is comprised of a proprietary, high-affinity, humanized anti-CD70 antibody stably and site-specifically conjugated to AS269, a potent microtubule inhibitor. After binding to CD70 expressed on tumor cells, ARX305 is internalized and catabolized, releasing the cytotoxic payload pAF-AS269 which inhibits cellular proliferation. ARX305 utilizes stable oxime conjugation chemistry, a non-cleavable PEG linker, and a membrane-impermeable payload to minimize premature payload release in circulation and associated off-target toxicity.
Methods
ARX305 was evaluated in multiple pre-clinical pharmacology and toxicology models using standard methodology.
Results
In vitro studies demonstrate that ARX305 selectively induces cytotoxicity of CD70-expressing tumor lines. In multiple in vivo xenograft or disseminated models, ARX305 induced significant tumor growth inhibition or regression whereas unconjugated antibody exhibited poor activity. The stable conjugation and cell-impermeable payload of ARX305 led to high serum stability, a long terminal half-life, and a similar exposure profile as unconjugated antibody in rodent pharmacokinetic studies. Repeat dose studies in cynomolgus monkeys demonstrated ARX305 was tolerated at exposures well above therapeutic exposures in mouse pharmacology studies, indicating a wide therapeutic index.
Conclusions
In summary, the highly selective and potent anti-tumor activity in multiple tumor types and wide pre-clinical therapeutic index of ARX305 support clinical evaluation of this next generation anti-CD70 ADC. ARX305 is currently in a phase 1 dose-escalation study in China.
Clinical trial identification
Editorial acknowledgement
Mark English, PhD, of Cancer Communications and Consultancy Ltd, Cheshire, UK, provided editorial assistance (funded by Ambrx).
Legal entity responsible for the study
Ambrx.
Funding
Ambrx and NovoCodex Biopharmaceuticals.
Disclosure
L. Skidmore: Financial Interests, Institutional, Full or part-time Employment: Ambrx. D. Mills, J.Y. Kim, K. Tatsukawa, N. Knudsen, J. Nelson, J. Wang, S. Zhang: Financial Interests, Personal, Full or part-time Employment: Ambrx.
Resources from the same session
67P - The effect of non-viral gene-immune therapy via OX40L or 4-1BBL on murine subcutaneous CT26 colon cancer model
Presenter: Olga Rakitina
Session: Poster session 09
68P - Dendritic polylysine with paclitaxel and triptolide codelivery for enhanced NSCLC ferroptosis through the accumulation of ROS
Presenter: Huae Xu
Session: Poster session 09
69P - Novel monoclonal antibodies can distinguish Cripto-1 from Cripto-3 proteins: Clinical implications and potential new biomarkers
Presenter: Josune Garcia-Sanmartin
Session: Poster session 09
70P - The human intratumor mycobiome is significantly influenced by an individual's race
Presenter: Dan Coster
Session: Poster session 09
72P - Impact of extended panel of genes for germline cancer testing
Presenter: Shaheenah Dawood
Session: Poster session 09
73P - Preclinical and clinical presentation of the nerve-driven tumor spread
Presenter: Dawid Sigorski
Session: Poster session 09
74P - Characterization of ERBB2 variation and their association with immune response in solid tumours
Presenter: Dong Wang
Session: Poster session 09
75P - Double-stranded RNA transfection induced anti-tumour effect mediated by dual RIG-I and TLR-3 immune pathways
Presenter: Jiayu Tai
Session: Poster session 09
76P - Improvement of whole-cell cancer vaccine anti-tumor effect by different injection methods
Presenter: Chin yang Chang
Session: Poster session 09
77P - Normative data on the sexual health questionnaires - QLQ-SHQ22, and the sexual domains of the QLQ-BR23/BR45 - for Norwegian general population with and without cancer
Presenter: Ragnhild Åsberg
Session: Poster session 09